跳至主要内容
临床试验/NCT05974332
NCT05974332尚未招募不适用

Serum Oncostatin M in Ulcerative Colitis Patients and Its Relation to Severity and Acute Exacerbation

Beni-Suef University0 个研究点目标入组 99 人开始时间: 2023年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
99
主要终点
Identify if oncostatin M is a good marker

研究概览

简要总结

Ulcerative colitis (UC) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

详细描述

Evaluation of UC activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. On the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (IBD), and evaluation of IBD using endoscopy is extremely important. However, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications.

Thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of UC have emerged, and fecal calprotectin (FC) and the fecal immunochemical occult blood test (FIT) are being widely used in clinical practice.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

性别
All
接受健康志愿者

入选标准

  • All patients aged >18 years and <80 years, of both gender who diagnosed to have UC and given the consent for participation in the study

排除标准

  • 1- Any patient with systemic inflammation as Bronchial asthma. 2- History of cancer or tumor. 3- Autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous

结局指标

主要结局

Identify if oncostatin M is a good marker

时间窗: 6 months

Diagnosis of Ulcerative colitis and follow up

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

mohamed gamal mohamed abdel aleem

Doctor

Beni-Suef University

相似试验

Oncostatin M in Ulcerative Colitis Patients | 临床试验